Comparison of Interscalene Catheter to Single Injection Interscalene Blocks for Total Shoulder Arthroplasties
Launched by MELINDA SEERING · May 19, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of pain management for patients undergoing total shoulder replacement surgery, also known as reverse shoulder arthroplasty. The researchers want to compare the effectiveness of a single injection of a pain-relieving medication called Exparel with a continuous pain relief method using an interscalene catheter. The goal is to see which method provides better pain control after surgery.
To be eligible for this trial, participants should be at least 18 years old and under 90, and they must be scheduled for this specific shoulder surgery. They also need to be in good health overall, which is classified as being in ASA class I, II, or III (these classes indicate how healthy a person is before surgery). Potential participants should be able to understand and provide consent for their involvement. It's important to note that certain medical conditions or treatments, like significant lung issues, chronic use of certain pain medications, or pregnancy, may disqualify someone from participating. Those who join the trial can expect to receive either the single injection or the catheter for pain relief, and they will be monitored closely to see how well their pain is managed after the surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Patients who have or are:
- • 1. Orthopedics service patients having reverse shoulder replacement surgery
- • 2. ASA class I, II, or III.
- • 3. Patients at least 18 years old but less than 90 years old.
- • 4. Patients giving informed consent.
- • 5. Non-Emergency Surgery
- Exclusion Criteria:
- Patients who have or are:
- • 1. An inability to cooperate during the block placement.
- • 2. Patients who do not meet criteria for a regional block: such as those on anti-coagulation,
- • 3. Significant pulmonary disease or allergy to medications used for peripheral nerve blocks (Exparel, Bupivacaine and Ropivacaine)
- • 4. Neuropathy of the planned extremity to block
- • 5. Documented Kidney Failure
- • 6. Documented Liver Failure
- • 7. A lack of or inability to give informed consent.
- • 8. Currently incarcerated.
- • 9. Pregnant
- • 10. Unable to communicate in English
- • 11. Chronic pre-operative opioid use (greater than 20 MME opioid used)
- • 12. Fracture
- • 13. Revision surgery
About Melinda Seering
Melinda Seering is a dedicated clinical trial sponsor committed to advancing medical research and enhancing patient care through innovative study designs and rigorous scientific protocols. With a strong focus on ethical standards and compliance, Melinda Seering collaborates with healthcare professionals and research institutions to facilitate the development of new therapies and interventions. Her leadership in the clinical trial landscape is characterized by a patient-centered approach, ensuring that the needs and safety of participants are prioritized throughout the research process. By leveraging her expertise and fostering partnerships, Melinda Seering aims to contribute significantly to the evolution of healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Iowa City, Iowa, United States
Patients applied
Trial Officials
Melinda Seering, MD
Principal Investigator
University of Iowa
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported